Cushing Syndrome

Urgently assess patients with florid or rapidly progressive hypercortisolism for complications that alter immediate management: severe hypertension, hypokalemia, edema, hyperglycemia, infection, thrombotic risk, neuropsychiatric deterioration, and cardiovascular symptoms. Obtain blood pressure, electrolytes, glucose, renal function, liver tests, and a resting ECG; pursue additional cardiovascular testing or imaging when symptoms or examination suggest cardiac disease. PubMedPubMedPerioperative Management of a Patient With Cushing Disease

When hypercortisolism is life-threatening, surgery is delayed, or surgery is not feasible, begin a rapid cortisol-lowering strategy rather than waiting for definitive treatment. For UFC greater than 5 but less than 10 times the upper limit of normal without life-threatening complications, higher-dose, relatively rapid-acting steroidogenesis-inhibitor monotherapy with osilodrostat, metyrapone, or ketoconazole and serum cortisol and/or UFC reassessment every 5-7 days is one recommended approach; block-and-replace therapy is an alternative. PubMedPubMedUpdate and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome

Correct clinically consequential hypokalemia, edema, and hypertension concurrently. Mineralocorticoid-receptor blockade can be effective for these manifestations, including during mifepristone, metyrapone, or osilodrostat therapy; avoid eplerenone with mifepristone because mifepristone increases eplerenone exposure. PubMedPubMedPerioperative Management of a Patient With Cushing Disease

First exclude exogenous corticosteroid exposure, the most common cause of Cushing syndrome. In patients with persistent clinical suspicion after that review, confirm endogenous hypercortisolism using late-night salivary cortisol, a 1-mg overnight dexamethasone suppression test, and/or 24-hour urinary free cortisol. BMJ+1BMJCushing syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice USOxford AcademicDiagnosis of Cushing's Syndrome: An Endocrine Society ...

For the overnight dexamethasone suppression test, administer dexamethasone 1 mg orally between 11 PM and midnight and measure serum cortisol between 8 AM and 9 AM the next morning. A morning cortisol below 1.8 micrograms/dL indicates normal suppression; failure to suppress requires confirmatory assessment in the clinical context. PubMed+1PubMedFlorid Cushing’s Syndrome - Endotext - NCBI Bookshelfcks nice org ukInvestigations | Diagnosis | Cushing's syndrome - CKS - NICE

Use tests of cortisol excess—not pituitary or adrenal imaging—as the first localization gate. Hypercortisolemia must be established before attempting etiologic differentiation, because incidental pituitary and adrenal lesions can misdirect management. PubMedPubMedFlorid Cushing’s Syndrome - Endotext - NCBI Bookshelf

Measure plasma ACTH after endogenous hypercortisolism is confirmed. Suppressed ACTH indicates ACTH-independent cortisol excess and should redirect imaging and management to the adrenal glands; nonsuppressed ACTH indicates ACTH-dependent disease requiring pituitary-versus-ectopic source assessment. BMJ+1BMJCushing syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice USPubMedFlorid Cushing’s Syndrome - Endotext - NCBI Bookshelf

An ACTH concentration above 20 ng/L establishes ACTH dependence in the Endotext diagnostic framework. Intermediate values are a gray zone because pituitary Cushing disease and adrenal pathology can overlap; repeat assessment and integrate the biochemical pattern rather than assigning etiology from a single indeterminate ACTH value. PubMedPubMedFlorid Cushing’s Syndrome - Endotext - NCBI Bookshelf

In ACTH-dependent Cushing syndrome, obtain gadolinium-enhanced pituitary MRI before invasive sampling. MRI detects only approximately 40%-52% of corticotroph tumors, so a negative study does not exclude Cushing disease. ScienceDirectScienceDirectEvaluation and treatment of Cushing’s syndrome - ScienceDirect

Surgical resection of the causative pituitary, adrenal, or ectopic neuroendocrine tumor is primary treatment for endogenous Cushing syndrome. For Cushing disease, transsphenoidal pituitary surgery is first-line; reported initial remission is approximately 70%-90% for microadenomas and 50%-65% for macroadenomas. accessdata fda+2accessdata fda202107Orig1s000 - accessdata.fda.govBMJCushing syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice USPubMedTreatment options for Cushing disease after unsuccessful ...

After persistent or recurrent Cushing disease, choose among repeat pituitary surgery, pituitary radiotherapy, medical therapy, and bilateral adrenalectomy according to localization, resectability, urgency of cortisol control, and patient preference. Medical therapy is also appropriate when surgery or radiotherapy is not feasible, in metastatic disease, or as a bridge when severe hypercortisolism requires immediate control. accessdata fda+2accessdata fda202107Orig1s000 - accessdata.fda.govOxford AcademicTreatment of Cushing's Syndrome: An Endocrine Society ...PubMedUpdate and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome

For adrenal cortisol excess, manage as an ACTH-independent source with adrenal-directed definitive treatment when an operable lesion is identified. For ectopic ACTH secretion, pursue resection of the ACTH-secreting tumor when feasible; steroidogenesis inhibitors can control cortisol excess regardless of source while localization, surgery, or oncologic treatment proceeds. BMJ+1BMJCushing syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice USPubMedCushing’s Syndrome - Endotext - NCBI Bookshelf

After pituitary surgery, interpret follow-up in the context of postoperative adrenal function and recurrent hypercortisolism risk. Initial surgery does not cure every patient, particularly macroadenomas, so persistent signs or biochemical evidence of cortisol excess should prompt reassessment for residual pituitary disease, ectopic ACTH secretion, or an incorrect initial localization. accessdata fdaaccessdata fda202107Orig1s000 - accessdata.fda.gov

Patients receiving medical therapy require serial assessment of cortisol control and drug toxicity. During rapid dose adjustment for substantial cortisol excess, repeat serum cortisol and/or UFC every 5-7 days; evaluate blood pressure, potassium, edema, liver tests, ECG/QT risk, and symptoms of hypocortisolism according to the selected agent. PubMed+1PubMedPerioperative Management of a Patient With Cushing DiseasePubMedUpdate and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome

If bilateral adrenalectomy is chosen after failure of pituitary-directed approaches, it provides definitive adrenal cortisol control but does not treat the pituitary ACTH source; plan long-term endocrine follow-up and surveillance for progressive corticotroph tumor behavior. accessdata fda+1accessdata fda202107Orig1s000 - accessdata.fda.govOxford AcademicTreatment of Cushing's Syndrome: An Endocrine Society ...